Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)

NCT00383097 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00383097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2006
Completion date
February 28, 2010
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkins lymphoma, non-hodgkin lymphoma